Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower total cardiovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · patients with type 2 diabetes mellitus
Intensive glycaemic control showed no clear difference in cardiovascular mortality compared with conventional glycaemic control (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · people with primary hypertension
1 finding from 1 review
Cardiovascular mortality · people with primary hypertension
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers may leads to lower cardiovascular mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review